Clinical Trials
28 trialsNCT04687969 2026-05-22
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Completed
NCT04955808 2026-05-13
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
Suspended
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT07485114 2026-03-20
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Tel-Aviv Sourasky Medical Center
Recruiting
NCT06349642 2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting
NCT03782207 2026-01-08
IMreal
Hoffmann-La Roche
Active not recruiting
NCT06717295 2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06194461 2025-06-27
LOCUS
AstraZeneca
Not yet recruiting
NCT03301493 2025-04-10
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
Completed
NCT04510129 2025-03-12
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
Recruiting
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03776123 2024-05-29
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Ipsen
Completed
NCT04410302 2023-10-16
Patient-Derived Xenografts to Reduce Cancer Health Disparities
University of California, Davis
Unknown
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT04072224 2023-01-26
Ablation
Centre Hospitalier Universitaire de Nīmes
Completed
NCT03232593 2022-08-24
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Hoffmann-La Roche
Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT00477919 2019-05-15
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
Completed
NCT03517332 2018-11-20
Circulating Tumor DNA Exposure in Peripheral Blood
Quantgene Inc.
Unknown
NCT03149523 2017-05-17
ExhauCRF
European Georges Pompidou Hospital
Unknown
NCT00310115 2016-09-23
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
M.D. Anderson Cancer Center
Completed
NCT01012011 2015-09-21
Regulatory Post Marketing Surveillance Study on Nexavar®
Bayer
Completed
NCT01482520 2014-05-14
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
Samsung Medical Center
Completed
NCT01466504 2013-04-15
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
Dartmouth-Hitchcock Medical Center
Terminated
NCT01230697 2010-10-29
SORHORM
University of Turin, Italy
Unknown